Dexnaaf 30 

Presentation: Dexnaaf 30 is available as enteric-coated capsules, each containing Dexlansoprazole 30 mg. Dexnaaf 30 is a product of Naafco Pharma Ltd. in Bangladesh and is usually available in blister packs. The capsule contains dual delayed-release granules.

Indications: Dexnaaf (Dexlansoprazole) is a proton pump inhibitor (PPI) indicated for:

• Healing of all grades of erosive esophagitis (EE) for up to 8 weeks.  
• Maintaining healing of EE and relief of heartburn for up to 6 months in adults and 16 weeks in patients 12 to 17 years ofage.
• Treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.  

Dosage and Administration:   Dexnaaf 30 capsules should be swallowed whole and can be taken without regard to food. Alternatively, the capsule can be opened, and the intact granules sprinkled on one tablespoon of applesauce and swallowed immediately. Granules should not be chewed.

• Maintenance of healed erosive esophagitis and relief of heartburn: The recommended dose is 30 mg once daily.
• Symptomatic Non-Erosive GERD: The recommended dose is 30 mg once daily for 4 weeks.
• Healing of erosive esophagitis: The recommended dose is 60 mg once daily for up to 8 weeks.

If a dose is missed, it should be taken as soon as possible. If it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule resumed.³A double dose should not be taken.

Side Effects: Common side effects of Dexnaaf (Dexlansoprazole) may include:

• Diarrhoea
• Abdominal pain
• Nausea
• Vomiting
• Flatulence

Precautions: Dexnaaf (Dexlansoprazole) is contraindicated in patients with known hypersensitivity to any component of the formulation.

Caution should be exercised in patients with:

• Gastric malignancy (possibility should be excluded prior to treatment).
• Clostridium difficile-associated diarrhoea.
• Risk factors for bone fracture.
• Hypomagnesaemia.
• Concomitant use of Dexnaaf with Methotrexate.
• Moderate hepatic impairment (a maximum daily dose of Dexnaaf 30 mg should be considered).

The safety and effectiveness of Dexnaaf in patients below 12 years of age have not been established. No dose adjustment is necessary for elderly patients or patients with renal impairment or mild hepatic impairment.

Use in Pregnancy and Lactation: There are no adequate and well-controlled studies with Dexlansoprazole in pregnant women. Dexnaaf should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known whetherDexlansoprazole is excreted in human breast milk. Caution should be exercised when Dexnaaf is administered to a nursing woman.

Storage: Store below 30°C temperature & in a dry place, protected from light. Keep all medicines out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.